We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.


GenoLogics Releases Clarity LIMS X as Part of Illumina SeqLab

Listen with
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

GenoLogics has announced the availability of Clarity LIMS X, an edition of its industry-leading laboratory informatics platform. Optimized for use with Illumina® SeqLab, the X Edition of Clarity LIMS provides positive sample tracking, maximizes quality and throughput, and improves turnaround time in population-scale genomics workflows.

The 2014 launch of the HiSeq X systems enabled labs to break the $1,000 barrier for human whole-genome sequencing. Labs are now addressing how to scale to throughput while maintaining a focus on quality and accuracy. The X Edition provides rapid scaling with automation and business logic built into preconfigured HiSeq X Series workflows.

Samples advance through the pipeline automatically, minimizing human interaction and the potential for error while enforcing quality standards. The X Edition of Clarity LIMS was designed based upon best practices from Genomics England Lab (GEL) and the Illumina FastTrack Services Lab, and is currently in use in both labs.

Clarity LIMS X Edition also provides e-signature, audit trails, and patient data security, making it suitable for regulated environments. According to Illumina Director of Scientific Research, Ryan Taft, Ph.D., “Clarity LIMS X closes the gap in providing a commercially available LIMS that includes out of the box instrument integration and positive sample tracking.”

“We are proud to partner with Illumina to provide the X Edition of Clarity LIMS for Illumina SeqLab,” says Michael Ball, CEO of GenoLogics. He adds, “This solution empowers scientists and clinicians to advance the understanding of disease and accelerate the integration of genomics into everyday healthcare.”